I3LUNG

IMMUNOTHERAPY IS STANDARD OF CARE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC), ADMINISTERED IN COMBINATION OR NOT WITH CHEMOTHERAPY. HOWEVER,  ONLY 30-50% OF THOSE PATIENTS BENEFIT FROM IO TREATMENT IN THE LONG TERM AND THERE IS AN INCREASING DEMAND FROM THE SCIENTIFIC COMMUNITY TO IDENTIFY PREDICTIVE BIOMARKERS FOR RESPONSE OTHER THAN THE CURRENT PROGRAMMED-DEATH LIGAND 1 (PD-L1). ON THE BASIS OF AN EVER-INCREASING DEMAND FROM THE MEDICAL COMMUNITY FOR A COMPREHENSIVE INTEGRATION OF CLINICAL AND MOLECULAR DATA TO IMPROVE BIOMARKERS PREDICTIONS IN ANSCLC, WE DESIGNED THE I3LUNG STUDY, FUNDED UNDER THE EU H2020 PROGRAM.  I3LUNG AIMS TO ACHIEVE THE HIGHEST PERFORMANCE IN PERSONALIZED MEDICINE THROUGH THE DESIGN OF A CUTTING-EDGE AI/ML MODELED ON MULTIMODAL PATIENT DATA, THAT WILL BE FURTHER IMPLEMENTED IN REAL-LIFE SETTINGS. THE STUDY WILL INTEGRATE MULTI-SOURCE DATA CONSIDERING BOTH CLINICAL INFORMATION AND MULTI-OMICS DATA, BY DEVELOPING A DATA STORAGE AND ELABORATION PLATFORM BASED ON THE PATIENT AVATAR SYSTEM. AI/ML WILL PUSH THE POTENTIAL OF DATA-DRIVEN TECHNIQUES TO IMPROVE THE CLINICAL DECISION PROCESS FOR ANSCLC PATIENT CANDIDATES FOR IO, TAILORING THE MOST INDIVIDUALIZED TREATMENTS. ADDITIONALLY, I3LUNG WILL ALSO DEVELOP AN INDIVIDUALIZED PATIENT DECISION AID SYSTEM (IPDAS) TO SUPPORT ANSCLC PATIENTS WITH EVIDENCE-BASED AND PERSONALIZED INFORMATION ABOUT THEIR DISEASE AND THE AVAILABLE THERAPEUTIC OPTIONS.

 
I3LUNG AT CLINICALTRIALS.GOV